drugset / Trial / NCT01806779
Combination Bupropion / Varenicline for Smoking Cessation in Male Smokers
Phase 2
Completed
376 enrolled
Duke University
National Institute on Drug Abuse (NIDA) · collabPhilip Morris USA · collab
RandomizedParallel-groupDouble-blindTreatment
Summary
Previous results from the investigators' Center have shown that combination treatment with Chantix and Zyban is more successful in helping men quit smoking. The investigators hope to replicate these findings with this study.
Timeline
- Start
- 2013-03
- Primary completion
- 2014-12
- Completion
- 2015-03
Outcome
Met primary endpoint
paper increased the abstinence rate relative to varenicline alone: 71.0% versus 43.8% (odds ratio = 3.14; 95% confidence interval = 1.11-8.92, p [one tailed] = .016). PMID 29054128 ↗
Publications
- Livingstone-Banks J, Fanshawe TR, Thomas KH, Theodoulou A, Hajizadeh A, Hartman L, Lindson N. Nicotine receptor partial agonists for smoking cessation. Cochrane Database Syst Rev. 2023 May 5;5(5):CD006103. doi: 10.1002/14651858.CD006103.pub8.
- Rose JE, Behm FM. Combination Varenicline/Bupropion Treatment Benefits Highly Dependent Smokers in an Adaptive Smoking Cessation Paradigm. Nicotine Tob Res. 2017 Aug 1;19(8):999-1002. doi: 10.1093/ntr/ntw283.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Varenicline | Small molecule | 1 mg | — |
| Subject | Zyban | Unknown | 150 mg | — |
| Background | Nicotine | Unknown | 21 mg | — |